Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065447 | 0.75 | ALDH1A1 (0.50) | ALDH1A1LMNANOTUMCYP1A2TSHR | |
| SCHEMBL4801016 | 0.70 | ALDH1A1 (0.41) | ALDH1A1LMNANOTUMCYP1A2TSHR | |
| SCHEMBL16013462 | 0.70 | MKNK1 (0.46) | MKNK1CHRM4 | |
| SCHEMBL16013479 | 0.70 | MKNK1 (0.46) | MKNK1CHRM4 | |
| SCHEMBL4800416 | 0.70 | ALDH1A1 (0.41) | ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL16013468 | 0.69 | MKNK1 (0.46) | MKNK1CHRM4 | |
| SCHEMBL5458654 | 0.69 | ALDH1A1 (0.41) | ALDH1A1LMNANOTUM | |
| SCHEMBL656087 | 0.69 | HRH2 (0.33) | ALDH1A1MKNK1CHRM4TSHR | |
| SCHEMBL5065400 | 0.69 | IKBKB (0.44) | ALDH1A1LMNACYP1A2 | |
| SCHEMBL1693615 | 0.69 | PIK3CD (0.43) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | FGFR3, FGFR1, ERBB3 | ALDH1A1 1911/4885LMNA 4401/4885MKNK1 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.